Myriam Chalabi, ESMO 2022: Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study
Neoadjuvant immunotherapy has shown promising responses in several cancer types. In this touchONCOLOGY interview Dr Myriam Chalabi (Netherlands Cancer Institute, Amsterdam, Netherlands) discusses the NICHE-2 study results, investigating patients with non-metastatic deficient DNA mismatch repair (dMMR) colon cancer, treated with one dose of ipilimumab and two doses of nivolumab and underwent surgery ≤6 weeks of registration.
The abstract entitled ‘Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study‘ Abstract LBA7, was presented at European Society for Medical Oncology (ESMO) 2022.
Questions:
- What are the unmet needs in the treatment of locally advanced MMR deficient colon cancer? (0:21)
- What were the aims, design and eligibility criteria of the NICHE-2 study? (1:29)
- What were the efficacy and safety endpoints and how well were they achieved? (2:07)
- What is the potential role of neoadjuvant immunotherapy in this treatment setting? (3:09)
- What questions remain unanswered and what further research is needed? (5:35)
Disclosures: Myriam Chalabi receives grant/research support from Roche, BMS and MSD; and is on the advisory board for BMS, and Numab.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
